Auspex Pharmaceuticals Stock Price

Stock Analysis Analyst Research Guru Analysis Stock Reports Competitors Fundamentals Financials Revenue/EPS SEC Filings Short Interest Dividend History Holdings Ownership Summary Institutional Holdings Insiders Form 4. 00 per share. (Reuters) - Shares of Auspex Pharmaceuticals Inc soared about 60 percent on Tuesday after the drug developer said its product for treating chorea, or involuntary movement associated with Huntington's disease, met the main goal in a late-stage study. Teva Pharmaceutical Industries Ltd. Find out More. View 13F filing holders of AUSPEX PHARMACEUTICALS INC COM. Teva sought to increase its Neurology unit as well as its product offering (Wainer, 2015). is trying to transform its generic and branded drug businesses, and it took another step in the latter category Monday by agreeing to pay $3. 36 per share after agreeing to be acquired by Teva Pharmaceutical Industries for $3. 5 billion to boost its portfolio of treatments for the central nervous system. Stocks recently featured in the blog include the Auspex Pharmaceuticals. In addition, increased prevalence of the disease is a key growth driver of the market. KENILWORTH, N. Get the latest Teva Pharmaceutical Industries Ltd. 5 Billion in the corporate control that has been experienced in the European Market in recent times. 28, 2015 (GLOBE NEWSWIRE) — Auspex Pharmaceuticals, Inc. Join GitHub today. The Zacks Analyst Blog Highlights: Auspex Pharmaceuticals, Infosys stock price may take a 10-15% knock as whistle blower brings back corporate governance issues to fore. OneWater Marine (ONEW) is due to price its IPO on October 24, while Progyny (PGNY), Phathom Pharmaceuticals (PHAT), Youdao (DAO), Cabaletta Bio (CABA) and Aesthetic Medical International Holdings Group (AIH) are scheduled to price on October 25. (NYSE and TASE:TEVA) and Auspex. Those few new-to-the-exchange companies represent an uptick from 2016, when the first pharmaceutical IPO didn't happen until early February. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing. Jan 10, 2018 · Teva's Stock Price Surge Against Its Predictable Woes after last month's announcement that the pharmaceutical manufacturer would lay off 14,000 employees, approximately one quarter of its. (NASDAQ:GMCR) to $168 from $134 on expectations of an acceleration of revenue and earnings growth given multiple new branded and…. For example, Auspex Pharmaceuticals had its IPO in January 2014 and completed two follow-on offerings within a year of its IPO. TEVA climbed nearly 1% to $62. S (about 15% of the U. for about US$3. Austedo is the first deuterated product to be reviewed by the FDA. 2bn all-cash takeover of Auspex Pharmaceuticals of the. 4 percent to Auspex's Friday closing price, the companies said on Monday. Lynn Dorsey Bleil is also a member of the Board of Directors of Alcon Inc. in 1997, a biopharmaceutical company, ultimately serving as Senior Vice President, Finance and Chief Financial Officer until March 2011, and then again from August 2011 until July 2015. 00 per Share, net to the seller in cash (less any required withholding taxes and without interest) (the "Offer Price. Auspex Pharmaceuticals stock doubled on promising news about a treatment for chorea, with Ruby Tuesday falling on news of falling sales and guest counts. in September 2013. Teva, the world’s biggest maker of generic medicines, offered $82 a share in cash and stock for Mylan, according to a statement. ’s (Teva) acquisition of Auspex Pharmaceuticals, Inc. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. John Schmid has served on our Board of Directors since June 2015. Teva Pharma (TEVA) to Acquire Auspex Pharma (ASPX) in $3. S (about 15% of the U. Healthcare coverage has also increased substantially over the past five years, from approximately 36% of the population in 2005 to 63% by the end of 2009. Auspex Pharmaceuticals, a US neurology drug company. 51 pct The drug developer says drug for treating chorea, or involuntary movement associated with Huntington's disease, met the main goal in a late-stage study. -- Auspex Pharmaceuticals, Inc. agreed to acquire Auspex Pharmaceuticals Inc. Ligand is a high-growth company with economic rights to some of the world's most important medicines. The FDAnews report EU MDR Compliance can help. , to price its stock and conduct an IPO any day now. is trying to transform its generic and branded drug businesses, and it took another step in the latter category Monday by agreeing to pay $3. Medipure Pharmaceuticals is a biopharmaceutical company conducting pioneering research in prescription pharmaceuticals. Teva will buy Auspex Pharmaceuticals for $3. Teva To Buy US Biotech Auspex Pharma In $3. Auspex Pharmaceuticals Inc. On March 31, Stifel Nicolaus analyst Stephen Willey downgraded his rating on Auspex Pharmaceuticals to hold with a $101 price target. Background Failed treatment trials are common in major depressive disorder and treatment-resistant depression, and remotely performed multifaceted, centralized structured interviews can potentially enhance signal detection by ensuring that enrolled patients meet eligibility criteria. 94, which is below then the sector average of 0. 5 billion to boost its portfolio of treatments for the central nervous system. : Teva Reinforces Leadership Position in CNS with Acquisition of Auspex. Get ASPX stock quote information for Auspex-Pharmaceuticals-Inc, including a stock overview, one-click scorecard, industry position, and the latest headlines. rebounds from recent losses; deals help. Compared to other peers in the Drug Manufacturers Major sector, Auspex’s earnings per share is currently at -5. The complaint alleged indian collusion schemes between six pharmaceutical firms including informal gatherings, telephone calls, and text messages. 2 billion in a move to strengthen its position on central nervous system condition treatments. Teva Pharmaceutical Industries said it would buy Auspex Pharmaceuticals for $101 a share in cash, or roughly $3. Jerusalem-based Teva said Monday that it will pay $101 per share, marking a 47 per cent premium to San. Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Auspex Pharmaceuticals, Inc. Aragon Pharmaceuticals. 0001 per share (the “Shares”), multiplied by the offer price of $101. Shah's broad knowledge of the life sciences industry will add crucial insights to our board of directors," said Laura Shawver, Ph. This is the initial public offering of Auspex Pharm aceuticals, Inc. Company Website www. They also assigned news stories about the biopharmaceutical company a news buzz of 0. 52 per share. is a biopharmaceutical company that licenses, develops, and commercializes targeted therapies for cancer and age-related macular degeneration. Industries, Ltd. 59% announced today that the acquisition of Auspex Pharmaceuticals, Inc. Metalloenzymes make up over 30% of all known enzymes in nature and are critically important for a wide range of biochemical processes and biological catalysis. Get instant access to a free live streaming chart of the Auspex Pharma Stock. Already a member? You have selected to change your default setting for the Quote. back stock information press releases events & presentations sec filings corporate governance investor resources Home Science Journey Immuno-Neurology Pipeline Literature Patients People Careers INVESTORS STOCK INFORMATION PRESS RELEASES EVENTS & PRESENTATIONS SEC FILINGS CORPORATE GOVERNANCE INVESTOR RESOURCES Contact. 2018, as calculated from the closing stock prices on. KEY RISKS Key risks to our price target include: (1) failure to meet sales expectations for Teva's branded pharmaceutical assets, including Copaxone. (Hebrew: טבע תעשיות פרמצבטיות בע"מ) is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel. 4 percent to Auspex's Friday closing price, the companies said on Monday. View detailed financial information, real-time news, videos, quotes and analysis on Auspex Pharmaceuticals Inc (:ASPX). Auspex Pharmaceuticals, Inc. HD INSIGHTS: On February 5, 2014, Auspex completed an IPO listing on the NASDAQ Exchange. The following content may not be associated with Alnylam Pharmaceuticals. Teva Pharmaceutical Industries Ltd. Overview: Detailed price quote, earnings report, user sentiment and news. 53 per cent on Friday. 2 percent to $63. Auspex Pharmaceuticals, Inc. teraparsecs. 1 billion buyout offer on Monday, saying the cash-and-stock proposal undervalues the company. , a deuteration company, engages in developing a pipeline of therapeutics that improves on existing drugs across various therapeutic areas. , there are many possible reasons to sell a stock, but only one reason to buy. 52 per share. (stock ticker symbol ASPX ). (Nasdaq: ASPX), a biopharmaceutical company that develops treatments for very rare diseases. So is Auspex Pharmaceuticals , Most stock quote data provided by BATS. You get price and volume information, plus stock charts, group rankings, exclusive stock ratings, stock news and more. The Zacks Analyst Blog Highlights: Auspex Pharmaceuticals, Infosys stock price may take a 10-15% knock as whistle blower brings back corporate governance issues to fore. 5 billion growing their CNS portfolio. Stock splits are used by Auspex Pharmaceuticals, Inc. 2705 per share for an aggregate principal amount of $84. Auspex employs its proprietary technology to create patent-protected, new chemical entities from known, clinically proven therapies. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. In October, the FDA approved Kite’s Yescarta for NHL. In Decemberthe attorneys general of 20 states filed a civil complaint accusing Teva Pharmaceutical of a coordinated indian to artificially maintain high prices for a generic antibiotic and diabetes drug. The estimated Net Worth of Gerald T Proehl is at least $16. Amryt Pharmaceuticals Anexon, Inc. The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. Common Stock $12. Considering the lack of treatments for HD, the drug’s approval will be a huge boost for the company. We are offering share s of our common stock. 2 billion ($A4. In February Teva - Israel's biggest company by market value and revenue - said it was ready to return to making acquisitions after a year focused on cutting. is buying Auspex Pharmaceuticals for about $3. AVEO Oncology is passionate in our pursuit of improving the lives of patients with cancer. Pharmaceutical company Pozen said the U. At that price, its offer for Synageva is worth only $217 a share, compared with the $230 cited in the companies’ announcement. Teva Pharmaceutical Industries Ltd. last year despite other. The FDAnews report EU MDR Compliance can help. Links to all outside sites are provided as a reference for our visitors. in 1997, a biopharmaceutical company, ultimately serving as Senior Vice President, Finance and Chief Financial Officer until March 2011, and then again from August 2011 until July 2015. Global huntington's disease therapeutics market is anticipated to grow at a steady CAGR in future. At Trevena, our mission is to deliver innovative medicines to patients and healthcare providers confronting serious medical conditions. A top Auspex Pharmaceuticals Inc. 65 points (1. Auspex is a company which specializes in central nervous research. Please note: Put and call options will begin trading on or about the date listed. Aragon Pharmaceuticals. On April 21st, Israel-based Teva Pharmaceutical made an unsolicited $40 billion offer for Mylan, a rival drugmaker based in the Netherlands. Teva Pharmaceutical Industries Ltd. In fact, the healthcare sector has been by far the. 001 per share. 5 million, which was based on the fair value of the non-cash consideration received on March 19, 2018, which consisted of 2,090,301 shares of publicly traded common stock of Processa. 2 billion in cash. 30, 2014, close. The chart below looks at all new issues from 2014 to 2018, mapping their performance from float price to close on September 18, against the amount of money raised. The truth is… There’s nothing that makes a stock price shoot for the moon faster than a takeover bid. Eagle Pharmaceuticals is a specialty pharmaceutical company realizing the untapped potential of life-saving medicines. 36 Target Price $101. teraparsecs. Thomas, McNerney and Panorama’s combined ownership interests thus amounted to 23. Jean-Jacques Bienaimé joined BioMarin’s Board in May 2005, the same time that he became the Company’s Chief Executive Officer, and was later named Chair of the Board in June 2015. 8 billion in the following year. In the past few months, Teva has returned to extra-organizational growth, and even announced the relatively large acquisition of Auspex Pharmaceuticals for $3. TEVA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 00 and closed at $15. in September 2013. You get price and volume information, plus stock charts, group rankings, exclusive stock ratings, stock news and more. Auspex does not yet have a product on the market. The chart is intuitive yet powerful, offering users multiple chart types including candlesticks, area, lines, bars and. About Emerald Bioscience, Inc. 00 per Share, net to the seller in cash (less any required withholding taxes and without interest) (the "Offer Price. Teva Pharmaceutical Industries said it would buy Auspex Pharmaceuticals for $101 a share in cash, or roughly $3. 5 billion in equity value. The price consists of $115 in cash and 0. What: Shares of orphan drugmaker Auspex Pharmaceuticals (UNKNOWN:ASPX. At that price, its offer for Synageva is worth only $217 a share, compared with the $230 cited in the companies’ announcement. Auspex Pharmaceuticals earned a media sentiment score of -4. Jean-Jacques Bienaimé Chairman and Chief Executive Officer BioMarin Pharmaceutical Inc. Register for a Free Account to gain greater access to The Wall Street Transcript right now Auspex Pharmaceuticals Inc. (NASDAQ:CNCE) entered into an asset purchase agreement worth up to $250 million with Vertex Pharmaceuticals, Inc. It acquired Ratiopharm for US$5 billion in the year 2010. com provide many key criteria and data for a stock to help you with your stock research. 2B Drug Merger. LA JOLLA, Calif. And after 5 years of intensive fairly large scale buying. Auspex Pharmaceuticals (NASDAQ:ASPX) prices its public offering of 4M shares (1M by existing stockholders) of common stock at $56. HD INSIGHTS: On February 5, 2014, Auspex completed an IPO listing on the NASDAQ Exchange. 5 billion buyout of Auspex Pharmaceuticals last month, hit the primary endpoint in a pivotal trial of tardive dyskinesia, a movement. Offering History for Ladenburg Thalmann and Co. Teva Pharmaceutical Industries Ltd. Stocks: Real-time U. 5 billion in cash to bolster its business of making drugs to treat disease of the central. The purchase, expected to. 31, giving it a market value of just under $54 billion. 1 billion buyout offer, saying the cash-and-stock proposal undervalues the company. 1984;34(7):939-944. (Nasdaq: ASPX), a biopharmaceutical company that develops treatments for very rare diseases. Insider trading activities including stock purchases, stock sales, and option exercises of ASPX listed in the above tables cannot be completely guaranteed as to their accuracy. “We are very pleased to have completed the acquisition of ARIAD Pharmaceuticals. EquityNet is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. We are offering share s of our common stock. GitHub is home to over 40 million developers working together to host and review code, manage projects, and build software together. Saks is a director of Auspex Pharmaceuticals, TONIX Pharmaceuticals, Depomed, Bullet Biotechnology, NuMedii and Velocity Pharmaceutical Development. Industries, Ltd. Detailed company description & address for Teva Pharmaceutical Industries Ltd. All of the stock option and RSU awards are subject to four-year vesting schedules. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. He noted, “Most of the Tesla Model S sales have occurred in the southern belt of USA. Auspex went public in January 2014 at a pre-money value of only $186. 2 billion in a move to strengthen its position on central nervous system condition treatments. For example, Auspex Pharmaceuticals had its IPO in January 2014 and completed two follow-on offerings within a year of its IPO. Please see below for complete disclosure, disclaimer and policy information. LA JOLLA, Calif. (ASPX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. The Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). 5 Billion in Anticipation of Competition over Copaxone Teva’s American Depositary Receipts rose 2. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing. Auspex Pharmaceuticals Inc (ASPX) Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases. Medipure Pharmaceuticals is a biopharmaceutical company conducting pioneering research in prescription pharmaceuticals. Apofore Corporation Apollo Medical Holdings, Inc. And on Friday, biotech Versartis surged about 50% from its offering price. Use the PitchBook Platform to explore the full profile. The merger closed in May 2015 after stockholders owning 78 percent of Auspex’s outstanding common stock (including 70. Trading volume was a total of 956. Get India stock market quotes, stock quote news india, latest share prices for FOLD. , a biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a public offering price of $12. 4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. SARs may be granted independently or in tandem with an Option at the time of grant of the related Option. Aires Pharmaceuticals Alfigen, Inc. Teva sought to increase its Neurology unit as well as its product offering (Wainer, 2015). 2 billion in a move to strengthen its position on central nervous system condition treatments. UnitedHealth will plan to acquire Catamaran Corp with its pharmacy division to create a stronger, new competitor in the market. in 1997, a biopharmaceutical company, ultimately serving as Senior Vice President, Finance and Chief Financial Officer until March 2011, and then again from August 2011 until July 2015. Teva Pharmaceutical Industries Ltd. Teva agreed to buy Auspex Pharmaceuticals for about $3. 00 per share in cash. Expenditure per capita on pharmaceuticals in Peru is one of the lowest in Latin America, providing significant opportunities for future growth. View today's stock price, news and analysis for MasTec Inc. 75 and is trading in the range of 42. 5 Thousand dollars as of 22 November 2016. Board of Directors. Among the companies with shares expected to actively trade in Wednesday's session are FedEx, American Apparel and Auspex Pharmaceuticals. Auspex is developing SD-809, a deuterium substituted version of the. 2B Drug Merger. TEVA climbed nearly 1% to $62. We are offering 7,000,000 shares of our common stock. In June 2014, Teva acquired Labrys Biologics for up to $825 million, the aim being to strengthen the company’s migraine pipeline. AUSPEX PHARMACEUTICALS, INC. 's 10-K Annual Report: Revenue - Product Highlight We have an obligation to make a payment to GSK of up to $2. Our DCF includes the contribution of sales of SD-809 in Huntington's disease, which Teva is gaining through the acquisition of Auspex Pharmaceuticals. is up nearly 180%. back stock information press releases events & presentations sec filings corporate governance investor resources Home Science Journey Immuno-Neurology Pipeline Literature Patients People Careers INVESTORS STOCK INFORMATION PRESS RELEASES EVENTS & PRESENTATIONS SEC FILINGS CORPORATE GOVERNANCE INVESTOR RESOURCES Contact. 5 billion in cash. The melee of the molecules continues as Teva Pharmaceuticals (TEVA) pressed its unsolicited offer for generic drug maker Mylan (MYL). 17 and a 52-week trading range of $14. (NYSE:TEVA) agreed to acquire Auspex Pharmaceuticals Inc. Get the latest Teva Pharmaceutical Industries Ltd. Online Dictionaries: Definition of Options|Tips Options|Tips. The company's first quarter average stock price was $67 per share. (Nasdaq:ASPX), a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases, will visit the Nasdaq MarketSite in Times Square. completed its purchase of Auspex Pharmaceuticals for. Auspex Pharmaceuticals, which was acquired three months ago for about $3. Auspex Pharma (NASDAQ: ASPX) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Benzinga. In Decemberthe attorneys general of 20 states filed a civil complaint accusing Teva Pharmaceutical of a coordinated indian to artificially maintain high prices for a generic antibiotic and diabetes drug. As soon as the market sees that generic margins are not turning as bad as expected, the stock has as we can see great potential. Companies with Orphan drugs continued to attract hefty premium in the valuations. ("Auspex" or the "Company") (NASDAQ GM: ASPX. : Teva Reinforces Leadership Position in CNS with Acquisition of Auspex. Auspex Pharmaceuticals soared 41. Expenditure per capita on pharmaceuticals in Peru is one of the lowest in Latin America, providing significant opportunities for future growth. but its stock price has lagged in a way. , where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. 66 and raised $84 million for the company. We estimate that the initial public of fering price of our common stock will be between $ and $ per s hare. Synageva Biopharma Corp (GEVA) Stock Price Surges 115% On Alexion Pharmaceuticals Inc (ALXN) $8. Dec 08, 2014 · Drug giant Merck said it will buy Cubist Pharmaceuticals for about $9. Teva share price moved up a marginal ~1% and Auspex stock rose by a significant ~41. Panorama owned approximately 7. 5 Billion in the corporate control that has been experienced in the European Market in recent times. The Dec 2008 Barr acquisition boosted Teva's product portfolio significantly. Stay in the loop! Get breaking news and. 5 billion in equity value. Headlines for Auspex Pharmaceuticals, Inc. On March 31, Stifel Nicolaus analyst Stephen Willey downgraded his rating on Auspex Pharmaceuticals to hold with a $101 price target. Auspex Pharmaceuticals, Inc. (ASPX) IPO - NASDAQ. (Hebrew: טבע תעשיות פרמצבטיות בע"מ) is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel. Shares fell 55 cents to $60. 53 per cent on Friday. ("Auspex" or the "Company") (NASDAQ GM: ASPX. Ag mortgage investment trust inc. -based Ra Pharmaceuticals (RARX) in a cash deal valued at about $2. 5 billion, the companies said Thursday. 5 billion buyout of Auspex Pharmaceuticals last month, hit the primary endpoint in a pivotal trial of tardive dyskinesia, a movement. AVEO Oncology is passionate in our pursuit of improving the lives of patients with cancer. Jerusalem-based Teva said Monday that it will pay $101 per share, marking a 47 per cent premium to San. 0 times peak sales. - August 29, 2019 - Eiger BioPharmaceuticals, Inc. Austedo was originally developed at Auspex Pharmaceuticals, which was acquired by Teva Pharmaceutical Industries Ltd (TEVA) in 2015 for $3. 1 billion, in the drug industry’s largest takeover attempt this year. (Name of Person Filing Statement) Common Stock, $0. Detailed company description & address for Teva Pharmaceutical Industries Ltd. 6 Million - read this article along with other careers information, tips and advice on BioSpace. Mirati Therapeutics Prices Public Offering Of Common Stock Credit Facility to Auspex Pharmaceuticals, Inc. The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. The Company identifies, develops, and commercializes novel therapeutic compounds for the treatment of osteo-renal diseases, including diseases related. They are AnaptysBio, Jounce Therapeutics and ObsEva SA, while industry followers anticipate a fourth, Visterra Inc. CTRX stock is soaring ahead of the bell, in response, while UNH shares are up moderately. Teva Pharma (TEVA) to Acquire Auspex Pharma (ASPX) in $3. John Schmid has served on our Board of Directors since June 2015. Auspex's current market cap stands at $1. Auspex Pharmaceuticals earned a media sentiment score of -4. Insider trading activities including stock purchases, stock sales, and option exercises of ASPX listed in the above tables cannot be completely guaranteed as to their accuracy. Ligand is a high-growth company with economic rights to some of the world's most important medicines. The company focuses on developing SD-254, a deuterium-substituted version of venlafaxine, for the treatment of depressive disorders. Food and Drug Administration again denied approval for its aspirin drug Yosprala. The stock is currently trading at $20. Stay in the loop! Get breaking news and. Auspex Pharmaceuticals, a US neurology drug company. TRACON Pharmaceuticals, Inc. DOW JONES, A NEWS CORP COMPANY News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. 0001 per share ("Shares"), of Auspex Pharmaceuticals, Inc. 5 Billion in the corporate control that has been experienced in the European Market in recent times. Use the PitchBook Platform to explore the full profile. 36 per share after agreeing to be acquired by Teva Pharmaceutical Industries for $3. markets Auspex Pharmaceuticals. Company Name AUSPEX PHARMACEUTICALS, INC. Avanir pharmaceuticals today launched a national, multi-channel campaign aimed at raising awareness of Pseudobulbar Affect, an often ignored and under treated neurologic condition that occurs secondary to certain neurologic injury or disease. 00 per share, representing total consideration of approximately $3. 2 Billion Mar. He was part of the founding management team of Arena Pharmaceuticals, Inc. Auspex does not yet have a product on the market. 75 and is trading in the range of 42. last year despite other. In Decemberthe attorneys general of 20 states filed a civil complaint accusing Teva Pharmaceutical of a coordinated indian to artificially maintain high prices for a generic antibiotic and diabetes drug. Market indices are shown in real time, except for the. A handful of analysts weighed in on Auspex Pharmaceuticals following Teva's acquisition announcement. Securities Registration Statement (S-1/A) BUSINESS. Auspex Pharmaceuticals soared more than 41% to $100. Use our contact form to ask questions, submit comments or request materials from Mylan. Saks is a director of Auspex Pharmaceuticals, TONIX Pharmaceuticals, Depomed, Bullet Biotechnology, NuMedii and Velocity Pharmaceutical Development. 5 billion all-cash deal structured as a two-step medium form merger pursuant to Section 251(h) of the DGCL. 2 billion in cash for Auspex Pharmaceuticals Inc. Global huntington's disease therapeutics market is anticipated to grow at a steady CAGR in future. Detailed company description & address for Teva Pharmaceutical Industries Ltd. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. Overview: Detailed price quote, earnings report, user sentiment and news. Auspex Pharmaceuticals, Inc. (Name of Subject Company) AUSPEX PHARMACEUTICALS, INC. Auspex went public in January 2014 at a pre-money value of only $186. biopharmaceutical firm Auspex Pharmaceuticals Inc for an equity value of $3. 's pipeline includes product candidates to address medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington's disease. —Shares of San Diego-based Auspex Pharmaceuticals. 0001 per share (the “Shares”), multiplied by the offer price of $101. completed its purchase of Auspex Pharmaceuticals for. April 2, 2014. , a deuteration company, engages in developing a pipeline of therapeutics that improves on existing drugs across various therapeutic areas.